CION Ameerpet
Epithelial ovarian cancer accounts for most ovarian cancer — and it is not one disease. The five subtypes arise differently, behave differently and respond to treatment differently, which is why the subtype line on your report matters as much as the stage.
Epithelial ovarian cancer accounts for the large majority of ovarian cancer, and it is treated in general conversation as a single condition. It is not. The five subtypes arise from different cells, carry different mutations, present at different stages, respond differently to chemotherapy and carry different outlooks.
The differences are substantial enough that researchers increasingly regard them as distinct diseases that happen to share an anatomical location. A high-grade serous cancer and a mucinous cancer have about as much in common as two cancers from different organs — they simply both happen to be found in the ovary.
This has a direct practical consequence. Survival statistics, treatment descriptions and general information about ovarian cancer are overwhelmingly describing high-grade serous, because it is by far the commonest. If you have one of the other subtypes, much of what you read will not apply to you — and knowing which one you have is what lets you tell the difference.
Different cells of origin, different mutations, different behaviour and different treatment responses.
Sharing an anatomical location rather than a biology. The differences are that substantial.
Because it is the commonest. If you have another subtype, much of what you read will not apply.
The subtypes even differ in how useful CA-125 is. High-grade serous cancers reliably produce it, which makes CA-125 genuinely valuable for monitoring response and detecting recurrence. Mucinous ovarian cancers frequently produce very little, so the marker can be normal even with active disease — and a woman with mucinous cancer followed on CA-125 alone may be falsely reassured. This is one of several places where applying general ovarian cancer practice to a less common subtype produces the wrong answer, and it is worth asking which marker your team is using for follow-up. Source: WHO classification of ovarian tumours; NCCN Ovarian Cancer guidelines.
Approximate characteristics. Your pathology report names one of these, and it changes the treatment conversation.
| Subtype | Typical characteristics | Treatment implications |
|---|---|---|
| High-grade serous | Commonest by far. Usually tubal origin. TP53 mutated. Often advanced at diagnosis. | Typically the most platinum-sensitive. Roughly half show HRD, opening maintenance therapy. |
| Low-grade serous | Uncommon. Slower growing. Younger women. Distinct mutations from high-grade. | Less chemo-sensitive but often hormone-receptor-positive, opening hormonal treatment options. |
| Clear cell | Frequently arises in endometriosis. Often earlier stage. More common in East and South Asian populations. | Typically less responsive to standard platinum chemotherapy. Higher thrombosis risk. |
| Endometrioid | Also linked to endometriosis. Often earlier stage and lower grade. | Generally responds reasonably. Can coexist with a separate womb cancer — both are checked. |
| Mucinous | Uncommon. Often large and unilateral. Frequently normal CA-125. | Less platinum-sensitive. A bowel or appendiceal primary must be excluded. |
*Note the recurring theme: the less common subtypes are frequently found earlier but are typically less responsive to standard chemotherapy. Neither fact alone tells you the outlook.
Find yours. Each has its own page linked from here for the full picture.
Accounts for the majority of epithelial ovarian cancer, and most general information about ovarian cancer is describing this. It usually begins in the fallopian tube rather than the ovary, carries a TP53 mutation in almost all cases, and typically presents at an advanced stage because it spreads across the peritoneum early.
The important counterweight: it is typically the most chemo-sensitive subtype, and roughly half show impaired DNA repair, which opens PARP-inhibitor-class maintenance therapy. See high-grade serous.
Despite the similar name, this is not simply a milder version of high-grade serous. It carries different mutations, occurs in younger women, and grows considerably more slowly — sometimes over years rather than months.
That slow growth cuts both ways: it is less responsive to chemotherapy, because chemotherapy targets rapidly dividing cells. But it is frequently hormone-receptor-positive, which opens hormonal treatment options that do not apply to high-grade disease. See low-grade serous.
Frequently arises in association with endometriosis, and is proportionally more common in East and South Asian populations than in Western ones — which matters here, since much published data comes from Western series.
It is often found at an earlier stage than high-grade serous, which is favourable, but it is typically less responsive to standard platinum chemotherapy. It also carries a higher risk of blood clots, which is worth knowing about and monitoring. See clear cell.
Resembles the lining of the womb under the microscope and is also associated with endometriosis. It is frequently found at an earlier stage and at a lower grade than high-grade serous, and generally responds reasonably to treatment.
The point specific to this subtype: it can coexist with a separate primary cancer of the womb lining. Both are checked when this subtype is found, and that is standard practice rather than a sign anything has gone wrong. See endometrioid.
Uncommon, often forming a large tumour confined to one ovary. The single most important step when this subtype is found is excluding a primary cancer of the bowel or appendix that has spread to the ovary, because mucinous tumours from those sites look very similar and need completely different treatment.
This usually means assessment of the bowel alongside the ovarian work-up. Mucinous ovarian cancers are also typically less platinum-sensitive and frequently produce little CA-125. See mucinous.
Worth mentioning here because they are frequently confused with epithelial cancers. Borderline tumours, also called tumours of low malignant potential, have abnormal cells that do not invade surrounding tissue the way a carcinoma does.
They occur more often in younger women, are usually confined to the ovary when found, carry a substantially better outlook, and are treated primarily with surgery — chemotherapy is frequently not needed. Fertility-sparing surgery is often possible. See borderline tumours.
Each of these is subtype-specific and frequently not covered unless raised.
One line on the pathology report. A great many women know their stage and not this.
It shapes what chemotherapy is likely to achieve, and whether other approaches should be considered.
Reliable in high-grade serous; frequently normal in mucinous even with active disease.
Low-grade serous is frequently hormone-receptor-positive, opening options that do not apply elsewhere.
Essential, because a bowel or appendiceal primary looks similar and needs different treatment.
A separate primary womb cancer can coexist. Standard practice to check both.
If you know your stage but not your subtype, ask. It is a single line on your pathology report and it changes what much of the general information you have read actually means for you.
It is one line on a pathology report and it shapes what treatment is likely to achieve. A great many women know their stage and not their subtype.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring your pathology report — the subtype is on it and it shapes the treatment conversation.
The commonest gap in this area is straightforward: women are told their stage, absorb it, and never learn their subtype — then read general information that describes high-grade serous and applies it to a clear cell or mucinous cancer where much of it does not hold.
Your first consultation at CION is free and runs to about 45 minutes. Bring your pathology report; the subtype is on it. Much of the useful work is establishing which disease you actually have, what that means for how treatment is likely to work, and which subtype-specific steps apply — excluding a bowel primary in mucinous disease, checking the womb in endometrioid, considering hormonal options in low-grade serous.
Chemotherapy and PARP-inhibitor-class maintenance therapy are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, alongside genetic counselling and BRCA and HRD testing. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Every case that raises a question is reviewed at a tumour board — which matters particularly for the less common subtypes.
Free and unhurried. Long enough to establish which disease you actually have and what follows from it.
The subtype is one line on it, and it changes what general information actually means for you.
Multidisciplinary review, which matters most for the less common subtypes seen infrequently.
BRCA and HRD testing, chemotherapy and maintenance therapy across 35+ centres.
General ovarian cancer survival statistics are dominated by high-grade serous, because it accounts for the majority of cases. That single fact distorts how those figures apply to everyone else.
A woman with early-stage clear cell or mucinous disease is reading numbers driven largely by advanced high-grade serous, which usually presents later. A woman with low-grade serous is reading numbers describing a cancer that behaves nothing like hers — hers grows over years rather than months. The headline figure describes a mixture, and the mixture is not her.
CION publishes its own one-year survival alongside the national figure so the comparison is visible: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. That too is across all subtypes and stages, and is a one-year figure rather than a cure rate. The genuinely useful conversation is with your oncologist, who can speak to your subtype, your stage and how your disease is actually behaving.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population, all subtypes.
The comparable national figure. *One-year survival; national registry data.
High-grade serous accounts for most cases, so it drives the headline number for everyone.
Low-grade serous behaves nothing like high-grade. The averaged figure describes neither well.
*One-year survival rates across all subtypes and stages. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups rather than individuals — discuss your own prognosis with your treating oncologist.
It is cancer arising from the epithelial cells of the ovary, fallopian tube or peritoneum, and it accounts for the large majority of ovarian cancer. The important point is that it is not one disease: five main subtypes are recognised — high-grade serous, low-grade serous, clear cell, endometrioid and mucinous — and they differ in their cell of origin, their mutations, the stage at which they typically present, how well they respond to chemotherapy and their outlook. The differences are substantial enough that they are increasingly regarded as distinct diseases sharing an anatomical location.
Because it shapes what treatment is likely to achieve and which options apply. High-grade serous is typically the most platinum-sensitive, and roughly half show impaired DNA repair, opening PARP-inhibitor-class maintenance therapy. Low-grade serous is less chemo-sensitive but frequently hormone-receptor-positive, opening hormonal treatment that does not apply elsewhere. Clear cell and mucinous are typically less responsive to standard platinum chemotherapy. There are also subtype-specific steps: excluding a bowel primary in mucinous disease, and checking the womb in endometrioid disease.
Yes, and it is worth asking, because it is a single line on your pathology report. Stage tells you how far disease has travelled; subtype tells you what kind of disease it is, and the two together shape the treatment conversation far more than either alone. It also determines how much of what you have read actually applies to you — general information and survival statistics about ovarian cancer are overwhelmingly describing high-grade serous, since it is the commonest, so much of it will not hold if you have one of the other subtypes.
No, and this catches people out. High-grade serous cancers reliably produce CA-125, which makes it genuinely valuable for monitoring response to treatment and detecting recurrence. Mucinous ovarian cancers frequently produce very little, so the marker can be entirely normal even with active disease — meaning a woman with mucinous cancer followed on CA-125 alone may be falsely reassured. If you have a subtype where CA-125 is unreliable, follow-up should rest on symptoms and imaging instead. It is worth asking which marker your team is actually using.
Because mucinous tumours that have spread to the ovary from the bowel or appendix look very similar under the microscope to a mucinous cancer that started in the ovary — and the two need completely different treatment. Establishing which you have is therefore essential rather than optional, and it usually means assessment of the bowel alongside the ovarian work-up. This is standard practice for this subtype rather than a sign anything has gone wrong, and it is worth confirming it has been done if you have a mucinous diagnosis.
They sit in a separate category and are frequently confused with them. Borderline tumours, also called tumours of low malignant potential, have abnormal cells that do not invade the surrounding tissue the way a carcinoma does — they sit genuinely between benign and malignant. They occur more often in younger women, are usually confined to the ovary when found, and carry a substantially better outlook than any of the epithelial carcinomas. They are treated primarily with surgery, chemotherapy is frequently not needed, and fertility-sparing surgery is often possible.
The first consultation is free and runs to about 45 minutes — bring your pathology report, since the subtype is on it and it changes what much of the general information you have read actually means for you. Chemotherapy and PARP-inhibitor-class maintenance therapy are delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, alongside genetic counselling and BRCA and HRD testing. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Every case is reviewed at a tumour board, which matters most for the less common subtypes.